F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin. nov, vol.68, issue.6, pp.394-424, 2018.

F. Cardoso, A. Costa, L. Norton, D. Cameron, T. Cufer et al., 1st International consensus guidelines for advanced breast cancer (ABC 1), Breast Edinb Scotl. juin, vol.21, issue.3, pp.242-52, 2012.

K. Jéhannin-ligier, E. Dantony, and Z. Uhry, Projection de l'incidence et de la mortalité en France métropolitaine en, 2017.

M. Colonna, E. Chatignoux, and L. Remontet, Estimation de l'incidence départementale des cancers en France métropolitaine, 2008.

F. Binder-foucard, A. Belot, P. Delafosse, L. Remontet, A. S. Woronoff et al., Estimation nationale de l'incidence et de la mortalité par cancer en France entre 1980 et 2012 -Partie 1 -Tumeurs solides

A. Cowppli-bony, Z. Uhry, L. Remontet, A. V. Guizard, N. Voirin et al., Survie des personnes atteintes de cancer en France métropolitaine 1989-2013 / Partie 1 -Tumeurs solides -7

E. Cordina-duverger and P. Guénel, Chapitre1 -Épidémiologie des cancers du sein, Cancer du Sein, pp.5-10, 2016.

V. Lavoué, C. Huchon, and E. Daraï, Prise en charge initiale du cancer épithélial de l'ovaire. Introduction aux Recommandations de pratiques cliniques françaises communes de FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY et labélisées par l'INCa, Gynécologie Obstétrique Fertil Sénologie. 1 févr, vol.47, issue.2, pp.93-97, 2019.

L. Vecchia and C. , Ovarian cancer: epidemiology and risk factors, Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP, vol.26, issue.1, pp.55-62, 2017.

V. Viassolo, A. Ayme, and P. O. Chappuis, Cancer du sein : risque génétique. Imagerie de la femme, 2016.

B. M. Norquist, M. I. Harrell, M. F. Brady, T. Walsh, M. K. Lee et al., Inherited Mutations in Women With Ovarian Carcinoma, JAMA Oncol. avr, vol.2, issue.4, pp.482-90, 2016.

A. De-pauw, L. Jolissaint, P. Fréneaux, É. Rouleau, D. Stoppa-lyonnet et al., Les formes héréditaires des cancers de l'ovaire, Bull Cancer (Paris). 1 avr, vol.99, issue.4, pp.453-62, 2012.

F. Eisinger, B. Bressac, D. Castaigne, P. Cottu, J. Lansac et al., Institut national du cancer. Cancer du sein -Quelles modalités de dépistage, Pathol Biol, vol.54, issue.4, pp.230-50, 2006.

H. Autorité-de-santé, Dépistage du cancer du sein en France : identification des femmes à haut risque et modalités de dépistage, 2014.

A. De-pauw, D. Stoppa-lyonnet, N. Andrieu, and B. Asselain, Estimation du risque individuel de cancer du sein : intérêt et limites des modèles de calcul de risque, Imag Femme. 1 juin, vol.24, issue.2, pp.97-104, 2014.

, Oncogénétique en 2017 /consultations et laboratoires, INCa, 2019.

C. Noguès, Chapitre2 -Prédisposition génétique au cancer du sein, Cancer du Sein

C. Chen, W. Feng, P. X. Lim, E. M. Kass, and M. Jasin, Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer, Annu Rev Cancer Biol. mars, vol.2, pp.313-349, 2018.

D. F. Easton, P. Pharoah, A. C. Antoniou, M. Tischkowitz, S. V. Tavtigian et al.,

, Gene-panel sequencing and the prediction of breast-cancer risk, N Engl J Med. 4 juin, vol.372, issue.23, pp.2243-57, 2015.

K. B. Kuchenbaecker, J. L. Hopper, D. R. Barnes, K. Phillips, T. M. Mooij et al., Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers, JAMA, vol.20, issue.23, pp.2402-2418, 2017.

C. Loveday, C. Turnbull, E. Ruark, R. Xicola, E. Ramsay et al., Germline RAD51C mutations confer susceptibility to ovarian cancer, Nat Genet. avr, vol.44, issue.5, pp.475-481, 2012.

C. Loveday, C. Turnbull, E. Ramsay, D. Hughes, E. Ruark et al., Germline mutations in RAD51D confer susceptibility to ovarian cancer, Nat Genet. août, vol.43, issue.9, pp.879-82, 2011.

L. Castéra, S. Krieger, A. Rousselin, A. Legros, J. Baumann et al., Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes, Eur J Hum Genet EJHG, vol.22, issue.11, pp.1305-1318, 2014.

J. Li, H. Meeks, B. Feng, S. Healey, H. Thorne et al., Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families, J Med Genet. janv, vol.53, issue.1, pp.34-42, 2016.

J. Moretta, P. Berthet, V. Bonadona, O. Caron, O. Cohen-haguenauer et al.,

, Recommandations françaises du Groupe Génétique et Cancer pour l'analyse en panel de gènes dans les prédispositions héréditaires au cancer du sein ou de l'ovaire. Bull Cancer (Paris), vol.105, pp.907-924, 2018.

S. E. Plon, D. M. Eccles, D. Easton, W. D. Foulkes, M. Genuardi et al., Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results, Hum Mutat, vol.29, issue.11, pp.1282-91, 2008.

C. Rousset-jablonski and A. Gompel, Screening for familial cancer risk: Focus on breast cancer. Maturitas, vol.105, pp.69-77, 2017.

M. King, J. H. Marks, and J. B. Mandell, New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2, Science, vol.302, issue.5645, pp.643-649, 2003.

M. J. Hall, J. E. Reid, L. A. Burbidge, D. Pruss, A. M. Deffenbaugh et al., BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer, Cancer. 15 mai, vol.115, issue.10, pp.2222-2255, 2009.

A. Antoniou, P. Pharoah, S. Narod, H. A. Risch, J. E. Eyfjord et al., Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies, Am J Hum Genet. mai, vol.72, issue.5, pp.1117-1147, 2003.

S. Chen and G. Parmigiani, Meta-analysis of BRCA1 and BRCA2 penetrance, J Clin Oncol Off J Am Soc Clin Oncol. 10 avr, vol.25, issue.11, pp.1329-1362, 2007.

N. Mavaddat, S. Peock, D. Frost, S. Ellis, R. Platte et al., Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE, J Natl Cancer Inst. 5 juin, vol.105, issue.11, pp.812-834, 2013.

P. O. Chappuis, V. Nethercot, and W. D. Foulkes, Clinico-pathological characteristics of BRCA1-and BRCA2-related breast cancer, Semin Surg Oncol. juin, vol.18, issue.4, pp.287-95, 2000.

S. R. Lakhani, M. J. Van-de-vijver, J. Jacquemier, T. J. Anderson, P. P. Osin et al., The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2, J Clin Oncol Off J Am Soc Clin Oncol. 1 mai, vol.20, issue.9, pp.2310-2318, 2002.

D. Silva, L. Lakhani, and S. R. , Pathology of hereditary breast cancer, Mod Pathol Off J U S Can Acad Pathol Inc. mai, vol.23, issue.2, pp.46-51, 2010.

S. R. Lakhani, S. Manek, F. Penault-llorca, A. Flanagan, L. Arnout et al., Pathology of ovarian cancers in BRCA1 and BRCA2 carriers, Clin Cancer Res Off J Am Assoc Cancer Res. 1 avr, vol.10, issue.7, pp.2473-81, 2004.

L. Bordeleau, S. Panchal, P. Goodwin, A. J. Van-den-broek, L. J. Van-'t-veer et al., Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers, J Clin Oncol Off J Am Soc Clin Oncol. 10 févr, vol.119, issue.1, pp.409-427, 2010.

K. Metcalfe, S. Gershman, H. T. Lynch, P. Ghadirian, N. Tung et al., Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers, Br J Cancer. 26 avr, vol.104, issue.9, pp.1384-92, 2011.

Y. C. Tai, S. Domchek, G. Parmigiani, and S. Chen, Breast cancer risk among male BRCA1 and BRCA2 mutation carriers, J Natl Cancer Inst. 5 déc, vol.99, issue.23, pp.1811-1815, 2007.

A. Moran, C. O'hara, S. Khan, L. Shack, E. Woodward et al., Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations, Fam Cancer. juin, vol.11, issue.2, pp.235-277, 2012.

Z. Baretta, S. Mocellin, E. Goldin, O. I. Olopade, and D. Huo, Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis. Medicine (Baltimore), vol.95, p.4975, 2016.

K. C. Kurnit, R. L. Coleman, and S. N. Westin, Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer, Curr Treat Options Oncol. 15 nov, vol.19, issue.12, p.1, 2018.

A. M. Oza, D. Cibula, A. O. Benzaquen, C. Poole, R. Mathijssen et al., Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial, Lancet Oncol. janv, vol.16, issue.1, pp.87-97, 2015.

M. R. Mirza, B. J. Monk, J. Herrstedt, A. M. Oza, S. Mahner et al., Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer, N Engl J Med, vol.01, issue.22, pp.2154-64, 2016.

, Institut national du cancer. Femmes porteuses d'une mutation de BRCA1 ou de BRCA2

, Détection précoce du cancer du sein et des annexes et stratégies de réduction du risque

A. J. Rijnsburger, I. Obdeijn, R. Kaas, M. Tilanus-linthorst, C. Boetes et al.,

, BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study, J Clin Oncol Off J Am Soc Clin Oncol. 20 déc, vol.28, issue.36, pp.5265-73, 2010.

T. N. Spiegel, K. A. Hill, and E. Warner, The attitudes of women with BRCA1 and BRCA2 mutations toward clinical breast examinations and breast self-examinations, J Womens Health, vol.18, issue.7, pp.1019-1043, 2002.

C. C. Riedl, N. Luft, C. Bernhart, M. Weber, M. Bernathova et al., Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density, J Clin Oncol Off J Am Soc Clin Oncol. 1 avr, vol.33, issue.10, pp.1128-1163, 2015.

X. Phi, S. Saadatmand, D. Bock, G. H. Warner, E. Sardanelli et al., Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis, Br J Cancer. 15 mars, vol.114, issue.6, pp.631-638, 2016.

I. Obdeijn, C. E. Loo, A. J. Rijnsburger, M. Wasser, E. Bergers et al., Assessment of false-negative cases of breast MR imaging in women with a familial or genetic predisposition, Breast Cancer Res Treat. janv, vol.119, issue.2, pp.399-407, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00535408

E. Warner, K. Hill, P. Causer, D. Plewes, R. Jong et al., Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging, J Clin Oncol Off J Am Soc Clin Oncol. 1 mai, vol.29, issue.13, pp.1664-1673, 2011.

E. Chéreau, C. Uzan, C. Balleyguier, C. J. De-paillerets, B. B. Caron et al.,

, Characteristics, treatment, and outcome of breast cancers diagnosed in BRCA1 and BRCA2 gene mutation carriers in intensive screening programs including magnetic resonance imaging, Clin Breast Cancer. avr, vol.10, issue.2, pp.113-121, 2010.

F. Sardanelli, F. Podo, F. Santoro, S. Manoukian, S. Bergonzi et al., Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk italian 1 study): final results, Invest Radiol. févr, vol.46, issue.2, pp.94-105, 2011.

I. Obdeijn, G. Winter-warnars, R. M. Mann, M. J. Hooning, M. Hunink et al., Should we screen BRCA1 mutation carriers only with MRI? A multicenter study, Breast Cancer Res Treat. avr, vol.144, issue.3, pp.577-82, 2014.

A. Pijpe, N. Andrieu, D. F. Easton, A. Kesminiene, E. Cardis et al., Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK), BMJ. 6 sept, vol.345, p.5660, 2012.
URL : https://hal.archives-ouvertes.fr/hal-02282766

C. Colin, C. Devic, A. Noël, M. Rabilloud, M. Zabot et al., DNA double-strand breaks induced by mammographic screening procedures in human mammary epithelial cells, Int J Radiat Biol, vol.87, issue.11, pp.1103-1115, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00640764

K. Passaperuma, E. Warner, P. A. Causer, K. A. Hill, S. Messner et al., Long-term results of screening with magnetic resonance imaging in women with BRCA mutations, Br J Cancer. 26 juin, vol.107, issue.1, pp.24-30, 2012.

N. M. Van-der-velde, M. Mourits, H. Arts, J. De-vries, B. K. Leegte et al., Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?, Int J Cancer. 15 févr, vol.124, issue.4, pp.919-942, 2009.

A. L. Oei, L. F. Massuger, J. Bulten, M. J. Ligtenberg, N. Hoogerbrugge et al., Surveillance of women at high risk for hereditary ovarian cancer is inefficient, Br J Cancer. 27 mars, vol.94, issue.6, pp.814-823, 2006.

B. Heemskerk-gerritsen, A. Jager, L. B. Koppert, A. Obdeijn, M. Collée et al., Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers, Breast Cancer Res Treat. 13 juill, 2019.

J. Zakhireh, B. Fowble, and L. J. Esserman, Application of screening principles to the reconstructed breast, J Clin Oncol Off J Am Soc Clin Oncol. 1 janv, vol.28, issue.1, pp.173-80, 2010.

A. I. Hagen, L. Maehle, N. Vedå, H. H. Vetti, A. Stormorken et al., Risk reducing mastectomy, breast reconstruction and patient satisfaction in Norwegian BRCA1/2 mutation carriers, Breast Edinb Scotl. févr, 2014.

M. Heijer, C. Seynaeve, R. Timman, H. J. Duivenvoorden, K. Vanheusden et al., Body image and psychological distress after prophylactic mastectomy and breast reconstruction in genetically predisposed women: a prospective long-term follow-up study, Eur J Cancer Oxf Engl, vol.48, issue.9, pp.1263-1271, 1990.

J. Gahm, M. Wickman, and Y. Brandberg, Bilateral prophylactic mastectomy in women with inherited risk of breast cancer--prevalence of pain and discomfort, impact on sexuality, quality of life and feelings of regret two years after surgery, Breast Edinb Scotl. déc, vol.19, issue.6, pp.462-471, 2010.

C. Marchetti, F. De-felice, I. Palaia, G. Perniola, A. Musella et al., Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers, BMC Womens Health. 12 déc, vol.14, p.150, 2014.

S. M. Domchek, T. M. Friebel, C. F. Singer, D. G. Evans, H. T. Lynch et al., Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality, JAMA. 1 sept, vol.304, issue.9, pp.967-75, 2010.

T. R. Rebbeck, N. D. Kauff, and S. M. Domchek, Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers, J Natl Cancer Inst. 21 janv, vol.101, issue.2, pp.80-87, 2009.

. Heemskerk-gerritsen-b-a.-m, C. Seynaeve, C. J. Van-asperen, M. Ausems, and J. M. Collée,

H. C. Doorn, Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction, J Natl Cancer Inst. mai, vol.107, issue.5, 2015.

A. Finch, K. Metcalfe, J. Lui, C. Springate, R. Demsky et al., Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene, Clin Genet. mars, vol.75, issue.3, pp.220-224, 2009.

A. Finch, K. A. Metcalfe, J. Chiang, L. Elit, J. Mclaughlin et al., The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation, Psychooncology. janv, vol.22, issue.1, pp.212-221, 2013.

L. S. Mørch, C. W. Skovlund, P. C. Hannaford, L. Iversen, S. Fielding et al., Contemporary Hormonal Contraception and the Risk of Breast Cancer, N Engl J Med, vol.07, issue.23, pp.2228-2267, 2017.

D. J. Hunter, G. A. Colditz, S. E. Hankinson, S. Malspeis, D. Spiegelman et al., Oral contraceptive use and breast cancer: a prospective study of young women, Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol, vol.19, issue.10, pp.2496-502, 2010.

M. Kumle, E. Weiderpass, T. Braaten, I. Persson, H. Adami et al., Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study, Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol, vol.11, issue.11, pp.1375-81, 2002.

S. Iodice, M. Barile, N. Rotmensz, I. Feroce, B. Bonanni et al., Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis, Eur J Cancer Oxf Engl, vol.46, issue.12, pp.2275-84, 1990.

D. Cibula, M. Zikan, L. Dusek, and O. Majek, Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis, Expert Rev Anticancer Ther. août, vol.11, issue.8, pp.1197-207, 2011.

P. G. Moorman, L. J. Havrilesky, J. M. Gierisch, R. R. Coeytaux, W. J. Lowery et al., Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis, J Clin Oncol Off J Am Soc Clin Oncol, vol.31, issue.33, pp.4188-98, 2013.

T. N. Sergentanis, A. Diamantaras, C. Perlepe, P. Kanavidis, A. Skalkidou et al., IVF and breast cancer: a systematic review and meta-analysis, Hum Reprod Update. févr, vol.20, issue.1, pp.106-129, 2014.

A. Gennari, M. Costa, M. Puntoni, L. Paleari, D. Censi et al., Breast cancer incidence after hormonal treatments for infertility: systematic review and meta-analysis of populationbased studies, Breast Cancer Res Treat. avr, vol.150, issue.2, pp.405-418, 2015.

K. A. Rodriguez-wallberg, S. Eloranta, K. Krawiec, A. Lissmats, J. Bergh et al., Safety of fertility preservation in breast cancer patients in a register-based matched cohort study, Breast Cancer Res Treat, vol.167, issue.3, pp.761-770, 2018.

J. Kotsopoulos, C. L. Librach, J. Lubinski, J. Gronwald, C. Kim-sing et al.,

, Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study, Cancer Causes Control CCC. déc, vol.19, issue.10, pp.1111-1120, 2008.

S. Silva-i-dos, P. A. Wark, V. A. Mccormack, D. Mayer, C. Overton et al., Ovulationstimulation drugs and cancer risks: a long-term follow-up of a British cohort, Br J Cancer. 2 juin, vol.100, issue.11, pp.1824-1855, 2009.

M. A. Rossing, J. R. Daling, N. S. Weiss, D. E. Moore, and S. G. Self, Ovarian tumors in a cohort of infertile women, N Engl J Med. 22 sept, vol.331, issue.12, pp.771-777, 1994.

C. Siristatidis, T. N. Sergentanis, P. Kanavidis, M. Trivella, M. Sotiraki et al.,

, Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer--a systematic review and meta-analysis, Hum Reprod Update. avr, vol.19, issue.2, pp.105-128, 2013.

T. Perri, D. Lifshitz, S. Sadetzki, B. Oberman, D. Meirow et al., Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers, Fertil Steril. mai, vol.103, issue.5, pp.1305-1317, 2015.

M. Jégu, S. Der, A. Morcel, K. Abadie, C. Fritel et al., Breast and ovarian cancer due to BRCA1&2 hereditary cancer predisposition syndrome and reproduction: literature review, J Gynecol Obstet Biol Reprod, vol.44, issue.1, pp.10-17, 2015.

M. B. Terry, Y. Liao, K. Kast, A. C. Antoniou, J. A. Mcdonald et al., The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations, JNCI Cancer Spectr. déc, vol.2, issue.4, p.78, 2018.

A. Toss, G. Grandi, A. Cagnacci, L. Marcheselli, S. Pavesi et al., The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation, Oncotarget. 7 févr, vol.8, issue.6, pp.9144-54, 2017.

J. Kotsopoulos, J. Lubinski, L. Salmena, H. T. Lynch, C. Kim-sing et al.,

, Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers, Breast Cancer Res BCR. 9 mars, vol.14, issue.2, p.42, 2012.

V. Mcguire, A. Felberg, M. Mills, K. L. Ostrow, R. Dicioccio et al., Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations, Am J Epidemiol, vol.160, issue.7, pp.613-621, 2004.

A. Valentini, J. Lubinski, T. Byrski, P. Ghadirian, P. Moller et al., The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation, Breast Cancer Res Treat, vol.142, issue.1, pp.177-85, 2013.

Q. Liu, J. Wuu, M. Lambe, S. Hsieh, A. Ekbom et al., Transient increase in breast cancer risk after giving birth: postpartum period with the highest risk (Sweden). Cancer Causes Control CCC, vol.13, pp.299-305, 2002.

J. E. Rossouw, G. L. Anderson, R. L. Prentice, A. Z. Lacroix, C. Kooperberg et al., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial, JAMA. 17 juill, vol.288, issue.3, pp.321-354, 2002.

A. Fournier, S. Mesrine, L. Dossus, M. Boutron-ruault, F. Clavel-chapelon et al., Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort, Breast Cancer Res Treat. juin, vol.145, issue.2, pp.535-578, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-01319982

J. Kotsopoulos, T. Huzarski, J. Gronwald, P. Moller, H. T. Lynch et al., Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a casecontrol study, Breast Cancer Res Treat. janv, vol.155, issue.2, pp.365-73, 2016.

J. Kotsopoulos, J. Gronwald, B. Y. Karlan, T. Huzarski, N. Tung et al., Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers, JAMA Oncol. 1 août, vol.4, issue.8, pp.1059-65, 2018.

T. R. Rebbeck, T. Friebel, T. Wagner, H. T. Lynch, J. E. Garber et al., Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group, J Clin Oncol Off J Am Soc Clin Oncol, vol.23, issue.31, pp.7804-7814, 2005.

F. Atsma, M. Bartelink, D. E. Grobbee, and Y. T. Van-der-schouw, Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis, Menopause N Y N. avr, vol.13, issue.2, pp.265-79, 2006.

C. M. Rivera, B. R. Grossardt, D. J. Rhodes, R. D. Brown, V. L. Roger et al., Increased cardiovascular mortality after early bilateral oophorectomy, Menopause N Y N. févr, vol.16, issue.1, pp.15-23, 2009.

T. M. Michelsen, A. Dørum, and A. A. Dahl, A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer, Gynecol Oncol. avr, vol.113, issue.1, pp.128-161, 2009.

J. S. Chapman, C. B. Powell, J. Mclennan, B. Crawford, J. Mak et al., Surveillance of survivors: follow-up after risk-reducing salpingo-oophorectomy in BRCA 1/2 mutation carriers, Gynecol Oncol. août, vol.122, issue.2, pp.339-382, 2011.

J. V. Cohen, L. Chiel, L. Boghossian, M. Jones, J. E. Stopfer et al., Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy, Fam Cancer. mars, vol.11, issue.1, pp.69-75, 2012.

J. Challberg, L. Ashcroft, F. Lalloo, B. Eckersley, R. Clayton et al., Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT, Br J Cancer. 28 juin, vol.105, issue.1, pp.22-29, 2011.

W. A. Rocca, J. H. Bower, D. M. Maraganore, J. E. Ahlskog, B. R. Grossardt et al., Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause, Neurology. 11 sept, vol.69, issue.11, pp.1074-83, 2007.

M. D'alonzo, E. Piva, S. Pecchio, V. Liberale, P. Modaffari et al., Satisfaction and Impact on Quality of Life of Clinical and Instrumental Surveillance and Prophylactic Surgery in BRCA-mutation Carriers, Clin Breast Cancer. 26 juill, 2018.

A. Finch, K. A. Metcalfe, J. K. Chiang, L. Elit, J. Mclaughlin et al., The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation, Gynecol Oncol. avr, vol.121, issue.1, pp.163-171, 2011.

R. Vermeulen, J. M. Beurden-m-van,-kieffer, E. Bleiker, H. B. Valdimarsdottir, and L. Massuger, Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study, Eur J Cancer Oxf Engl, vol.84, pp.159-67, 1990.

J. L. Chan, S. Senapati, L. Johnson, L. Digiovanni, C. Voong et al., Risk factors for sexual dysfunction in BRCA mutation carriers after risk-reducing salpingo-oophorectomy, Menopause N Y N. 16 juill, 2018.

L. Lombardi, S. M. Bramanti, A. Babore, L. Stuppia, C. Trumello et al., Psychological aspects, risk and protective factors related to BRCA genetic testing: a review of the literature, Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 15 juin, 2019.

A. Brédart, J. Kop, M. Fall, S. Pelissier, C. Simondi et al., Anxiety and specific distress in women at intermediate and high risk of breast cancer before and after surveillance by magnetic resonance imaging and mammography versus standard mammography, Psychooncology, vol.21, issue.11, pp.1185-94, 2012.

S. Delaloge, T. Bachelot, F. Bidard, M. Espie, E. Brain et al., Breast cancer screening: On our way to the future, Bull Cancer, vol.103, issue.9, pp.753-63, 2016.

J. A. Beaver, D. Jelovac, S. Balukrishna, R. Cochran, S. Croessmann et al., Detection of cancer DNA in plasma of patients with early-stage breast cancer, Clin Cancer Res Off J Am Assoc Cancer Res. 15 mai, vol.20, issue.10, pp.2643-50, 2014.

S. A. Cohen, C. L. Scherr, and D. M. Nixon, An iPhone Application Intervention to Promote Surveillance Among Women with a BRCA Mutation: Pre-intervention Data, J Genet Couns. avr, vol.27, issue.2, pp.446-56, 2018.

J. D. Seidman, P. Zhao, and A. Yemelyanova, « Primary peritoneal » high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer, Gynecol Oncol. mars, vol.120, issue.3, pp.470-473, 2011.

E. Leblanc, F. Narducci, I. Farre, J. Peyrat, S. Taieb et al., Radical fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes? Rationale and preliminary development, Gynecol Oncol. 1 juin, vol.121, issue.3, pp.472-478, 2011.

C. Sénéchal, F. Reyal, N. Callet, P. This, C. Noguès et al., Hormonotherapy for breast cancer prevention: What about women with genetic predisposition to breast cancer?, Bull Cancer, vol.103, issue.3, pp.273-81, 2016.

J. Cuzick, I. Sestak, B. Bonanni, J. P. Costantino, S. Cummings et al., Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data, Lancet Lond Engl. 25 mai, vol.381, issue.9880, pp.1827-1861, 2013.

H. D. Nelson, M. Smith, J. C. Griffin, and R. Fu, Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force, Ann Intern Med. 16 avr, vol.158, issue.8, pp.604-618, 2013.

S. Mocellin, P. Pilati, M. Briarava, and D. Nitti, Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials, J Natl Cancer Inst. févr, vol.108, issue.2, 2016.

J. Cuzick, I. Sestak, J. F. Forbes, M. Dowsett, J. Knox et al., Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, doubleblind, randomised placebo-controlled trial, Lancet Lond Engl. 22 mars, vol.383, issue.9922, pp.1041-1049, 2014.

P. E. Goss, J. N. Ingle, J. E. Alés-martínez, A. M. Cheung, R. T. Chlebowski et al., Exemestane for breast-cancer prevention in postmenopausal women, N Engl J Med. 23 juin, vol.364, issue.25, pp.2381-91, 2011.

, Diagnostic prénatal, interruption médicale de grossesse, diagnostic pré-implantatoire et formes héréditaires de cancers -Site des professionnels -Agence de la biomédecine, 2006.

U. Menon, J. Harper, A. Sharma, L. Fraser, M. Burnell et al., Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer, Hum Reprod Oxf Engl. juin, vol.22, issue.6, pp.1573-1580, 2007.

J. Gietel-habets, C. De-die-smulders, . Derks-smeets-i-a.-p, A. Tibben, V. Tjan-heijnen et al., Support needs of couples with hereditary breast and ovarian cancer during reproductive decision making, Psychooncology. juill, vol.27, issue.7, pp.1795-801, 2018.